# Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes

> **NCT01378117** · PHASE4 · COMPLETED · sponsor: **Emory University** · enrollment: 90 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Hospitalization
- Hyperglycemia

## Interventions

- **DRUG:** Sitagliptin
- **DRUG:** glargine
- **DRUG:** lispro

## Key facts

- **NCT ID:** NCT01378117
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2012-05
- **Final completion:** 2012-06
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2018-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01378117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01378117, "Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01378117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*